Peptides for hypertrophy in athletes: what the evidence actually shows

What did @drbrunosander actually say?

Honestly? Very little of substance. The transcript is largely incoherent, referencing vague ideas about "community," "policies," and something about a book. There are no specific peptide claims, no dosing protocols, and no named compounds. The actual content of this video, based on the transcript, cannot be meaningfully fact-checked because no factual claims were made.

What we do have is context: the caption explicitly advertises injectable peptide services for athletes seeking hypertrophy, with a phone number in Belo Horizonte, Brazil. That promotional framing, combined with hashtags like injetaveis (injectables) and peptídeos, tells us more than the spoken content does. The video appears to be a direct-to-consumer advertisement for clinical peptide services, likely including growth hormone secretagogues or recovery compounds, though none are named explicitly in the transcript.

Bottom line: the transcript reads like an auto-generated caption error or a non-Portuguese audio track being misread. We cannot quote a single coherent claim from what was said.

Does the science back this up?

Since no specific scientific claims were made, we can only evaluate what the video implies: that injectable peptides produce hypertrophy benefits in athletes. That claim, in general, has mixed support depending on the compound involved.

Growth hormone secretagogues like CJC-1295 and ipamorelin do stimulate GH release. A study by Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 significantly elevated IGF-1 levels in healthy adults. Whether elevated IGF-1 translates to meaningful hypertrophy in already-healthy athletes is a different question. The anabolic signal exists; the magnitude of benefit in trained individuals is less clear.

BPC-157, popular in recovery contexts, has a strong preclinical record. Sikiric et al. (2018, Current Pharmaceutical Design) documented tendon, muscle, and gut healing effects in rodent models. Human trial data remains sparse. TB-500, another recovery peptide, similarly lacks robust human clinical trials. Marketers often extrapolate from animal data, and that gap matters.

Advertising injectables for hypertrophy without naming the compounds or discussing individual risk profiles is a red flag, not a scientific endorsement.

What did they get wrong (or right)?

We cannot credit or penalize the creator for specific scientific claims because none were clearly made in the transcript. However, the promotional structure of the video raises legitimate concerns.

Advertising injectable peptide services directly on TikTok, with a phone number and no visible informed consent framework, sidesteps the kind of clinical context that responsible prescribing requires. Peptides like MK-677 (ibutamoren) are frequently marketed for muscle gain but are not approved drugs in most jurisdictions. MK-677 increases GH and IGF-1 but also raises fasting glucose and may worsen insulin sensitivity (Nass et al., 2008, Annals of Internal Medicine). That trade-off is rarely discussed in promotional content.

The video does not appear to make false claims, but it also does not provide the information a patient would need to make an informed decision. Omission in this context is its own problem. An advertisement for injectables that names no compounds, discloses no risks, and provides no regulatory context is not responsible patient education.

What should you actually know?

If you are an athlete considering peptide therapy for hypertrophy or recovery, here is what the evidence actually supports, without the sales pitch.

• Growth hormone secretagogues can raise IGF-1 levels in healthy adults, but evidence for hypertrophy outcomes specifically in trained athletes is limited and largely indirect.
• BPC-157 and TB-500 have promising animal data for tissue repair, but no large-scale human randomized controlled trials have confirmed these effects in athletic populations.
• Compounded peptides are not equivalent to pharmaceutical-grade approved drugs. Purity, sterility, and concentration can vary significantly between compounding pharmacies.
• In Brazil, peptide regulation falls under ANVISA guidelines, and many compounds used in sports optimization exist in a regulatory gray zone. Patients should ask for documentation.
• Any injectable therapy carries infection risk, and that risk scales with preparation quality and administration technique.

Seek a provider who names the compounds they are prescribing, explains the evidence base, discloses risks, and does not advertise on TikTok with only a phone number. That is not an unreasonable standard.